Oregon 2022 Regular Session

Oregon House Bill HB4025

Introduced
2/1/22  
Refer
2/1/22  

Caption

Relating to pseudoephedrine; prescribing an effective date.

Impact

This legislation will amend the current Oregon Revised Statute (ORS) 475.230, thereby expanding the role of pharmacy interns in handling sensitive prescriptions. The bill takes effect on January 1, 2023, and it aims to enhance access to medications containing pseudoephedrine while maintaining stringent controls on their distribution to prevent misuse. By enabling interns to perform these transfers, the bill is expected to alleviate some burden from licensed pharmacists, allowing for a more efficient workflow in pharmacy operations.

Summary

House Bill 4025 proposes amendments to the existing regulations surrounding the transfer of drugs containing pseudoephedrine and ephedrine. The bill allows pharmacy interns, in addition to licensed pharmacists and pharmacy technicians, to transfer these drugs under specific conditions. This legislative change is intended to streamline processes within pharmacies and ensure that trained personnel are available to facilitate these transactions, especially considering the common use of such medications for various health issues, including allergies and colds.

Contention

While the bill supports increased accessibility and reduces pressure on pharmacists, there may be concerns about the potential for misuse of pseudoephedrine, which is regulated due to its association with illegal drug production. Opponents may argue that introducing interns into this process could lead to lapses in judgment or compliance with regulations, potentially increasing the risk of controlled substances being improperly distributed. Moreover, there may also be opposition on grounds of local legislative authority or the adequacy of training provided to interns in handling such medications.

Companion Bills

No companion bills found.

Previously Filed As

OR HB1399

Ephedrine and pseudoephedrine products.

OR HB1463

Pseudoephedrine; require manufacturers to pay fees to National Association of Drug Diversion Investigators to support NPLE.

OR SB2733

NPLEx; require manufacturers of certain pseudoephedrine or ephedrine products to pay fees to support the administration of.

OR HB4947

Health: pharmaceuticals; manufacturers of products containing ephedrine or pseudoephedrine; require to participate in a national logging system. Amends secs. 7340 & 7340a of 1978 PA 368 (MCL 333.7340 & 333.7340a).

OR HB4948

Controlled substances: other; sentencing guidelines for retail sale of products containing ephedrine or pseudoephedrine; modify. Amends sec. 13m, ch. XVII of 1927 PA 175 (MCL 777.13m). TIE BAR WITH: HB 4947'25

OR SB878

Modifies provisions relating to pharmaceutical drugs and devices

OR HB1962

Modifies provisions relating to limits on selling or purchasing certain drugs

OR SB1005

Relating to swiping driver licenses.

OR HB2055

Relating to swiping driver licenses.

OR HB3046

Relating to pharmacy; prescribing an effective date.

Similar Bills

OR HB3223

Relating to prescription drugs; prescribing an effective date.

AZ SB1710

pharmacy benefits; patient steering; prohibition

MI SB0403

Health occupations: pharmacists; dispensing certain addiction medications without undue delay; require. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7333c.

KY HB772

AN ACT relating to pharmaceutical manufacturers.

MS SB2544

Mississippi Active Pharmaceutical Ingredient Quality Assurance Act; enact to impose certain provisions for compounding.

AZ SB1458

pharmacy board; civil penalties

SD SB14

Modify provisions related to the practice of pharmacy.

TX HB5248

Relating to a pilot program for the safe disposal of prescription drugs, including controlled substance prescription drugs.